CL
TTPH

Croft-Leominster’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Croft-Leominster’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-325
Closed -$308K – 195
2015
Q2 		$308K Buy
+325
New +$266K 0.06% 130

Other funds holding TTPH

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Croft-Leominster's TTPH Position: Q3 2015 in Review

Croft-Leominster sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2015, closing a stake of 325 shares — an estimated $308K sold.

Croft-Leominster first reported a position in TTPH in Q2 2015 and held it in 1 quarter. The position peaked at $308K in Q2 2015. 105 funds tracked by Wall St. Rank hold TTPH as of Q3 2015.

  • Croft-Leominster reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Croft-Leominster sold 325 Tetraphase Pharmaceuticals, Inc. shares in Q3 2015, an estimated $308K.
  • Croft-Leominster first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2015 and held it in 1 quarter.
  • Croft-Leominster's Tetraphase Pharmaceuticals, Inc. position peaked at $308K in Q2 2015.
  • 105 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2015.

Based on Croft-Leominster's 13F filing for Q3 2015, filed 16 Nov 2015.